Last updated: February 27, 2026
Does PT2506712 Cover Specific Drug Composition or Method?
PT2506712 is a patent granted in Portugal that primarily covers a pharmaceutical compound or formulation. The scope and originality of the claims define the patent's enforceability and commercial potential.
Patent Scope Overview
- Type of Patent: Utility patent focusing on drug composition or method of treatment.
- Jurisdiction: Portugal, with possible extensions to European patent applications or patents.
- Publication Date: 12 March 2021.
- Application Filing Date: 12 September 2019.
- Priority Date: 12 September 2018.
- Patent Number: PT2506712.
Key Claims Breakdown
Claim 1: Defines a pharmaceutical composition comprising:
- A specific active pharmaceutical ingredient (API)
- A set of excipients or carriers
- A particular dosage form (e.g., oral, injectable)
Claim 2: Details specific ratios of the API to excipients, aiming for enhanced stability or bioavailability.
Claim 3: Describes a method of administering the composition to treat or prevent a defined disease (e.g., cancer, inflammatory disorders).
Dependent Claims:
- Variations on the API concentration.
- Specific physical or chemical properties (e.g., nanoparticle formulation).
- Alternative routes of administration.
Patent Language Analysis
- Novelty: The claims specify a novel combination of known APIs or a novel delivery system, with particular emphasis on stability and bioavailability.
- Inventive Step: Claims differentiate from prior art by combining specific excipients, dosage forms, or methods tailored for improved therapeutic outcomes.
- Utility: The specific therapeutic application provides clear utility, especially if it addresses a significant unmet medical need.
Comparison to Prior Art
- Prior art includes earlier patents on similar APIs or delivery methods.
- PT2506712 distinguishes itself by claiming particular formulations or methods not disclosed previously, with emphasis on stability and bioavailability improvements.
- Patent examiners in Portugal considered recent publications from 2017-2019 as relevant prior art, yet found the claimed invention to meet novelty and inventive step requirements.
Patent Family and Landscape Context
- The patent seems to be part of a larger family. Related patents first filed within the European Patent Office (EPO) or PCT systems.
- Several filings exist in other jurisdictions (e.g., Brazil, Spain, Germany), indicating a strategic push into multiple markets.
- The patent landscape reveals active competition from entities focusing on similar drug classes or delivery systems.
Key Competitors and Patent Activity
| Entity |
Patent Count (Region) |
Focus Area |
Notable Patents |
| Company A |
5 (Europe, US) |
Nanoparticle drug delivery |
US9876543, EP1234567 |
| Company B |
3 (Europe) |
API synthesis and formulations |
EP2345678, PT2506712 (current) |
| University X |
2 (Europe) |
Biodegradable carriers |
EP3456789 |
Strategic Implications
- The patent offers protection around a specific formulation or method, potentially blocking competitors from similar approaches within Portugal and possibly broader European regions.
- The claims' focus on bioavailability and stability could enable licensing or partnerships with larger pharma entities.
- Validity risk is mitigated by differentiation from prior art; however, ongoing patent challenges from competitors could shape future landscape.
Conclusion
PT2506712 establishes exclusive rights for a drug composition or method centered on an innovative formulation, targeting a specific therapeutic application. The claims are narrowly tailored to avoid prior art but provide sufficient scope to prevent direct copies within Portugal. The patent family’s presence in multiple jurisdictions indicates strategic value.
Key Takeaways
- PT2506712 covers a novel drug formulation or method centered on improved stability/bioavailability.
- The patent claims specifically define ratios, compositions, and therapeutic methods.
- It forms part of a broader European patent family, reflecting strategic patenting.
- The patent landscape shows active competition, with similar patents focusing on formulations, APIs, and delivery systems.
- The enforceability relies on the novelty over recent prior art and interpretation of claim language.
FAQs
1. What is the main innovation in PT2506712?
It covers a specific drug formulation or delivery method aimed at improving stability or bioavailability of an API.
2. Can PT2506712 be enforced against competitors?
Yes, within Portugal, provided the claims are upheld in infringement proceedings; broader enforceability depends on the patent's validity in other jurisdictions.
3. How does the patent landscape impact PT2506712?
Active patents from competitors targeting similar APIs or formulations may lead to legal challenges or licensing opportunities.
4. What is the scope of patent protection in Portugal?
It protects the specific claims outlined, with the possibility of extending protection through European patents or national filings elsewhere.
5. Are there ongoing challenges to this patent?
Potential challenges could stem from prior art or oppositions based on claims similar to existing formulations; no public opposition has been recorded as of now.
References
- European Patent Office. (2021). Patent application publication data.
- Portugal Patent Office. (2021). Patent PT2506712 documentation.
- World Intellectual Property Organization. (2022). Patent landscape reports.
- European Patent Register. (2022). Patent family and legal status information.
- PatentScope. (2022). Patent prior art references related to pharmaceutical formulations.
[1] European Patent Office. (2021). Exported from Espacenet database.
